Haemanthamine

Name: Haemanthamine
Brand: MedChemExpress
SKU: HY-114489A
Rating: 4.5 (1 reviews)

Cat. No.: HY-114489A: FAQs
Data Sheet SDS COA Handling Instructions Technical Support

Haemanthamine is a crinine-type alkaloid isolated from the Amaryllidaceae plants with potent anticancer activity. Haemanthamine targets ribosomal that inhibits protein biosynthesis during the elongation stage of translation. Haemanthamine has pro-apoptotic, antioxidant, antiviral, antimalarial and anticonvulsant activities.

For research use only. We do not sell to patients.

Haemanthamine Chemical Structure

CAS No. : 466-75-1

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	Get quote
10 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Haemanthamine:

Haemanthamine hydrochloride Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Parasite Isoform Specific Products:

View All Isoforms

Amebae Coccidia Leishmania Mite Plasmodium Toxoplasma Trypanosoma Schistosome

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	0.3 μM Compound: Haemanthamine	Cytotoxicity against human A2780 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay Cytotoxicity against human A2780 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay	[PMID: 34536668]
A549	IC₅₀	0.3 μM Compound: Haemanthamine	Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay	[PMID: 34536668]
A549	IC₅₀	2.5 μM Compound: 2	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 23190013]
A549	IC₅₀	3 μM Compound: 14	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31513408]
AGS	IC₅₀	0.3 μM Compound: Haemanthamine	Cytotoxicity against human AGS cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay Cytotoxicity against human AGS cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay	[PMID: 34536668]
BEAS-2B	IC₅₀	5 μM Compound: 2	Cytotoxicity against human BEAS2B cells after 48 hrs by MTT assay Cytotoxicity against human BEAS2B cells after 48 hrs by MTT assay	[PMID: 23190013]
BT-549	IC₅₀	0.3 μM Compound: Haemanthamine	Cytotoxicity against human BT-549 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay Cytotoxicity against human BT-549 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay	[PMID: 34536668]
COLO 201	IC₅₀	0.3 μM Compound: Haemanthamine	Cytotoxicity against human COLO201 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay Cytotoxicity against human COLO201 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay	[PMID: 34536668]
HeLa	IC₅₀	1.3 μM Compound: 14	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31513408]
HepG2	IC₅₀	4.8 μM Compound: 2	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 23190013]
HL-60	IC₅₀	0.3 μM Compound: Haemanthamine	Cytotoxicity against human HL-60 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay Cytotoxicity against human HL-60 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay	[PMID: 34536668]
HL-60	IC₅₀	1.4 μM Compound: 2	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 23190013]
HT-29	IC₅₀	0.3 μM Compound: Haemanthamine	Cytotoxicity against human HT-29 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay Cytotoxicity against human HT-29 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay	[PMID: 34536668]
HT-29	IC₅₀	2.1 μM Compound: 2	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 23190013]
Jurkat	IC₅₀	0.3 μM Compound: Haemanthamine	Cytotoxicity against human Jurkat cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay Cytotoxicity against human Jurkat cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay	[PMID: 34536668]
K562	IC₅₀	2.5 μM Compound: 2	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 23190013]
MCF7	IC₅₀	0.3 μM Compound: Haemanthamine	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay	[PMID: 34536668]
MDA-MB-231	IC₅₀	0.3 μM Compound: Haemanthamine	Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay	[PMID: 34536668]
MOLT-4	IC₅₀	0.3 μM Compound: Haemanthamine	Cytotoxicity against human MOLT-4 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay Cytotoxicity against human MOLT-4 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay	[PMID: 34536668]
NCI-H1299	IC₅₀	0.3 μM Compound: Haemanthamine	Cytotoxicity against human NCI-H1299 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay Cytotoxicity against human NCI-H1299 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay	[PMID: 34536668]
NHDF	IC₅₀	0.3 μM Compound: Haemanthamine	Cytotoxicity against human NHDF cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay Cytotoxicity against human NHDF cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay	[PMID: 34536668]
PANC-1	IC₅₀	0.3 μM Compound: Haemanthamine	Cytotoxicity against human PANC-1 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay Cytotoxicity against human PANC-1 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay	[PMID: 34536668]
SAOS-2	IC₅₀	0.3 μM Compound: Haemanthamine	Cytotoxicity against human SAOS-2 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay Cytotoxicity against human SAOS-2 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay	[PMID: 34536668]
SK-BR-3	IC₅₀	0.3 μM Compound: Haemanthamine	Cytotoxicity against human SK-BR-3 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay Cytotoxicity against human SK-BR-3 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay	[PMID: 34536668]
SK-OV-3	IC₅₀	3.7 μM Compound: 14	Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31513408]
SW480	IC₅₀	0.3 μM Compound: Haemanthamine	Cytotoxicity against human SW480 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay Cytotoxicity against human SW480 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay	[PMID: 34536668]

In Vitro

Haemanthamine (1-100 µM; 24-48 hours; A2780 cells) treatment shows a time- and dose-dependent decrease in cell viability^[2].
Haemanthamine (10 µM; 24-72 hours; A2780 cells) treatment leads to a significant inhibition of A2780 cell proliferation^[2].
Haemanthamine binds at the A-site cleft of the peptidyl transferase center on the large ribosomal subunit, creating unique molecular interactions with the 25S rRNA. Haemanthamine has a highly specific inhibitory effect on pre-rRNA processing, leading to the activation of a p53-dependent antitumoral surveillance pathway known as nucleolar stress^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	A2780 ovarian cancer cells
Concentration:	1 µM, 10 µM, 50 µM, 100 µM
Incubation Time:	24 hours, 48 hours
Result:	Showed a time- and dose-dependent decrease in cell viability.

Cell Proliferation Assay^[2]

Cell Line:	A2780 ovarian cancer cells
Concentration:	10 µM
Incubation Time:	24 hours, 48 hours, 72 hours
Result:	Led to a significant inhibition of A2780 cell proliferation.

In Vivo

A pharmacokinetic study of Haemanthamine in rats shows a rapid distribution phase of 30 min, a half-life of 70.4 min, and a major clearance through renal elimination. The high distribution volume of 13.7 L/kg suggests a high intracellular penetration, and its plasmatic concentration remains higher than 1 μM for at least 1 hr after a single 10-mg/kg administration^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

301.34

Formula

C₁₇H₁₉NO₄

CAS No.

466-75-1

Appearance

Solid

Color

White to off-white

SMILES

O[C@@H](C1)[C@@]2(C=C3)C4=CC(OCO5)=C5C=C4C[N@@]1[C@@]2([H])C[C@@H]3OC

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (331.85 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.3185 mL	16.5926 mL	33.1851 mL
5 mM	0.6637 mL	3.3185 mL	6.6370 mL
10 mM	0.3319 mL	1.6593 mL	3.3185 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 0.83 mg/mL (2.75 mM); Clear solution

This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 0.83 mg/mL (2.75 mM); Clear solution

This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 0.83 mg/mL (2.75 mM); Clear solution

This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Select Batch:

Data Sheet (278 KB) SDS (251 KB)

COA (253 KB)

Handling Instructions (2659 KB)

References

[1]. Pellegrino S, et al. The Amaryllidaceae Alkaloid Haemanthamine Binds the Eukaryotic Ribosome to Repress Cancer Cell Growth. Structure. 2018 Mar 6;26(3):416-425.e4. [Content Brief]

[2]. Seifrtová M, et al. Haemanthamine alters sodium butyrate-induced histone acetylation, p21WAF1/Cip1 expression, Chk1 and Chk2 activation and leads to increased growth inhibition and death in A2780 ovarian cancer cells. Phytomedicine. 2017 Nov 15;35:1-10. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.3185 mL	16.5926 mL	33.1851 mL	82.9628 mL
	5 mM	0.6637 mL	3.3185 mL	6.6370 mL	16.5926 mL
	10 mM	0.3319 mL	1.6593 mL	3.3185 mL	8.2963 mL
	15 mM	0.2212 mL	1.1062 mL	2.2123 mL	5.5309 mL
	20 mM	0.1659 mL	0.8296 mL	1.6593 mL	4.1481 mL
	25 mM	0.1327 mL	0.6637 mL	1.3274 mL	3.3185 mL
	30 mM	0.1106 mL	0.5531 mL	1.1062 mL	2.7654 mL
	40 mM	0.0830 mL	0.4148 mL	0.8296 mL	2.0741 mL
	50 mM	0.0664 mL	0.3319 mL	0.6637 mL	1.6593 mL
	60 mM	0.0553 mL	0.2765 mL	0.5531 mL	1.3827 mL
	80 mM	0.0415 mL	0.2074 mL	0.4148 mL	1.0370 mL
	100 mM	0.0332 mL	0.1659 mL	0.3319 mL	0.8296 mL

Haemanthamine Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Haemanthamine466-75-1ApoptosisInfluenza VirusParasiteAlkaloidanticancerribosomecytotoxicantioxidantantiviralantimalarialanticonvulsantpro-apoptoticantiproliferativeInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Haemanthamine

Customer Review

Other Forms of Haemanthamine:

Haemanthamine Related Antibodies

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Parasite Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Haemanthamine Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Haemanthamine Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report